Hypertension and Endstage Renal Disease

Abstract

Spanish

French

OBJECTIVE:

To review current literature regarding the development of hypertensive renal disease, its epidemiology, and its pathophysiology. This review focuses on strategies to slow or halt the progression of endstage renal disease (ESRD) in hypertension, including the role of blood pressure control, different types of antihypertensive agents, early treatment, and dietary considerations.

DATA SOURCES:

Information was retrieved from searching the MEDLINE database for articles consisting of epidemiologic studies, clinical studies, and review articles pertaining to hypertension and ESRD. Information also was obtained from the US Renal Data System annual data reports.

STUDY SELECTION:

Emphasis was placed on clinical trials in the English language addressing issues in hypertension and ESRD. Clinical trials reporting relationships between blood pressure control and ESRD, as well as those comparing different antihypertensive agents, were evaluated.

DATA EXTRACTION:

The methodology and results from clinical trials were evaluated. Studies were assessed according to the measures of renal function used, baseline data collected, degree of blood pressure control, and antihypertensive therapy.

DATA SYNTHESIS:

Clinical trials including patients with essential hypertension, diabetes mellitus, and renal insufficiency of various etiologies were evaluated. The recommendations from these evaluations were based on study design and the types of populations used (i.e., blacks vs. whites, diabetics vs. nondiabetics).

CONCLUSIONS:

Blood pressure control is currently the most important strategy to slow or halt the progression of renal insufficiency in hypertensive individuals. Whether specific antihypertensives are renal protective is still controversial, but results from clinical trials are promising.

Get full access to this article

View all access options for this article.

References

Drizd

Dannenberg

Engel

. Blood pressure levels in persons 18–74 years of age in 1976–80 and trends in blood pressure from 1960–80 in US. In: Vitals and Health Statistics, Hyattsville, MD: US Department of Health and Human Services, Public Health Services, National Center for Health Statistics. July 1986, Series 11, No. 234.

National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group report on hypertension and chronic renal failure. Arch Intern Med 1991; 151: 1280–7.

Blythe

Maddux

. Hypertension as a causative diagnosis of patients entering endstage renal disease programs in the United States from 1980 to 1986. Am J Kidney Dis 1991; 18: 33–7.

Moore

Porush

. Hypertension and renal insufficiency: Recognition and management. Am Fam Physician 1992; 45: 1248–56.

US Renal Data System. USRDS 1992 annual data report. Bethesda, MD: The National Institute of Diabetes and Digestive and Kidney Diseases, August 1991.

Healthy people 2000 national health promotion and disease prevention. Washington, DC: US Department of Human Health Services, Public Health Service, September 1990.

Ordonez

Hiatt

Quesenberry

. Epidemiologic features of treated end-stage renal disease in a large prepaid health plan. Am J Public Health 1990; 80: 47–9.

McClellan

Tuttle

Issa

. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 1988; 12: 285–90.

Tierney

McDonald

Luft

. Renal disease in hypertensive adults: Effect of race and type II diabetes mellitus. Am J Kidney Dis 1989; 13: 485–93.

10.

Easterling

. Racial factors in the incidence and causation of end-stage renal disease (ESRD). Trans Am Soc Artif Intern Organs 1977; 23: 28–33.

11.

Rostand

Kirk

Rutsky

Pate

. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982; 306: 1276–9.

12.

Luke

. Can renal failure due to hypertension be prevented? Hypertension 1991; 18 (suppl I):I-139–42.

13.

Feld

Van Liew

Brentjens

Boylan

. Renal lesions and proteinuria in the spontaneous hypertensive rat made normotensive by treatment. Kidney Int 1981; 20: 606–14.

14.

Rostand

Brown

Kirk

Rutsky

Dustan

. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320: 684–8.

15.

Batuman

Landy

Maesaka

Wedeen

. Contribution of lead to hypertension with renal impairment. N Engl J Med 1983; 309: 17–21.

16.

Shulman

Ford

Hall

Blaufox

Simon

Langford

Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the Hypertension Detection and Follow-up Program. Hypertension 1989; 13 (suppl I):I-80–93.

17.

Samuelsson

. Proteinuria as a prognostic factor during long term hypertensive care. Drugs 1988; 35 (suppl 5):48–54.

18.

Klahr

. The kidney in hypertension—villain and victim. N Engl J Med 1989; 320: 731–3.

19.

Cusi

Ferrari

Salardi

Ferrandi

Tripodi

Barlassina

A primary kidney abnormality in essential hypertension. Contrib Nephrol 1987; 54: 1–8.

20.

Sealey

Blumenfeld

Bell

Pecker

Sommers

Laragh

. On the renal basis for essential hypertension: Nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertension 1988; 6: 763–77.

21.

Sommers

Melamed

. Renal pathology of essential hypertension. Am J Hypertens 1990; 3: 583–7.

22.

Aurell

. Aspects of the role of intraglomerular pressure as a cause of progressive renal damage. Drugs 1988; 35 (suppl 5):42–7.

23.

Cusi

Bianchi

. The kidney in the pathogenesis of hypertension. Semin Nephrol 1991; 11: 523–37.

24.

Dworkin

Benstein

. Impact of antihypertensive therapy on progressive kidney damage. Am J Hypertens 1989; 2 (suppl):S162–72.

25.

Lafferty

Brenner

. Are glomerular hypertension and “hypertrophy” independent risk factors for progression of renal disease? Semin Nephrol 1990; 10: 294–304.

26.

Weir

. Impact of blood pressure control on renal function. Int Proc J 1989; 1: 56–63.

27.

Levy

Talner

Coel

Holle

Stone

. Renal vasculature in essential hypertension: Racial differences. Ann Intern Med 1978; 88: 12–6.

28.

Campese

Parise

Karubian

Bigazzi

. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991; 18: 805–12.

29.

Frohlich

Messerli

Oigman

Ventura

Sundgaard-Riise

. Greater renal vascular involvement in the black patient with essential hypertension. Miner Electrolyte Metab 1984; 10: 173–77.

30.

Brancati

Whittle

Whelton

Seidler

Klag

. The excess incidence of diabetic end-stage renal disease among blacks. JAMA 1992; 268: 3079–84.

31.

Baldwin

Neugarten

. Hypertension and renal diseases. Am J Kidney Dis 1987; 10: 186–91.

32.

Baldwin

Neugarten

. Role of hypertension in the evolution of renal diseases. Contrib Nephrol 1987; 54: 63–76.

33.

Parving

Smidt

Andersen

Svendsen

. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175–9.

34.

Bergstrom

Alvestrand

Bucht

Gutierrez

. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 1986; 25: 1–6.

35.

Brazy

Stead

Fitzwilliam

. Progression of renal insufficiency: Role of blood pressure. Kidney Int 1989; 35: 670–4.

36.

Mogensen

. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982; 285: 685–8.

37.

Ferder

Daccordi

Martello

Panzalis

Inserra

. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19 (suppl II):II-237–42.

38.

Bakris

. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707–8.

39.

Hartford

Wendelhag

Berglund

Wallentin

Ljungman

Wikstrand

. Cardiovascular and renal effects on long-term antihypertensive treatment. JAMA 1988; 259: 2553–7.

40.

Pedersen

Mogensen

. Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest 1976; 36: 231–7.

41.

Pettinger

Lee

Reisch

Mitchell

. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension 1989; 13: 766–72.

42.

Klahr

Levey

Sandberg

Williams

. Major results of the feasibility study of the modification of diet in renal disease study (abstract). Kidney Int 1989; 35: 195.

43.

Samuelsson

Wikstrand

Wilhelmsen

Berglund

. Heart and kidney involvement during antihypertensive treatment. Acta Med Scand 1984; 215: 305–11.

44.

Walker

Neaton

Cutler

Neuwirth

Cohen

. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. JAMA 1992; 268: 3085–91.

45.

Farnett

Mulrow

Linn

Lucey

Tuley

. The J-curve phenomenon and the treatment of hypertension. JAMA 1991; 265: 489–95.

46.

Fletcher

Bulpitt

. How far should blood pressure be lowered? N Engl J Med 1992; 326: 251–4.

47.

Tolins

Raij

. Antihypertensive therapy and the progression of chronic renal disease. Are there renoprotective drugs? Semin Nephrol 1991; 11: 538–48.

48.

Bauer

Reams

. Do calcium antagonists protect the human hypertensive kidney? Am J Hypertens 1989; 2: S173–8.

49.

Yoshida

Kawamura

Ikoma

Fogo

Ichikawa

. Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989; 36: 626–35.

50.

Epstein

. Calcium antagonists and renal protection, current status and future perspectives. Arch Intern Med 1992; 152: 1573–84.

51.

Bjorck

Nyberg

Mulec

Granerus

Herlitz

Aurell

. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471–4.

52.

Demarie

Bakris

. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 113: 987–8.

53.

Hommel

Parving

Mathiesen

Edsberg

Nielsen

Giese

. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 1986; 293: 467–70.

54.

Lewis

Hunsicker

Bain

Rohde

. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62.

55.

Zucchelli

Zuccala

Borghi

Fusaroli

Sasdelli

Stallone

Comparison of calcium channel blocker and ACE inhibitor therapy on the progression of renal insufficiency. Contrib Nephrol 1990; 81: 255–63.

56.

Zucchelli

Zuccala

Gaggi

. Calcium channel blockers: Effects on progressive renal disease. Am J Kidney Dis 1991; 17 (suppl 1):94–7.

57.

The Fifth Joint National Committee (JNC-V). The Report of the Joint National Committee on Detection, Evaluation and Treatment of Hypertension. Arch Intern Med 1993; 153: 154–83.

58.

Hebert

Bay

. On the natural tendency to progressive loss of remaining kidney function in patients with impaired renal function. Med Clin North Am 1990; 74: 1011–25.

59.

Levey

Perrone

Madias

. Serum creatinine and renal function. Ann Rev Med 1988; 39: 465–90.

60.

Oldrizzi

Rugiu

Maschio

. Hypertension and progression of renal failure in patients on protein-restricted diet. Contrib Nephrol 1987; 54: 134–43.

61.

Barrientos

Arteaga

Rodicio

Ude

Alcazar

Ruilope

. Role of the control of phosphate in the progression of chronic renal failure. Miner Electrolyte Metab 1982; 7: 127–133.

62.

Vega

Grundy

. Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism. Kidney Int 1988; 33: 1160–8.

63.

Locatelli

Alberti

Granziani

Buccianti

Redaelli

Griangrande

. Prospective, randomized, multicentre trial of the effect of protein restriction on the progression of chronic renal insufficiency. Lancet 1991; 337: 1299–1304.

64.

Ihle

Becker

Whitworth

Charlwood

Kincaid-Smith

. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 1989; 321: 1773–7.

65.

Klahr

. The modification of diet in renal disease study. N Engl J Med 1989; 320: 864–6.